What is the Oligonucleotide Synthesis Market Size in 2026?
The global oligonucleotide synthesis market was valued at USD 4.90 billion in 2025 and is projected to grow from USD 5.39 billion in 2026 to nearly USD 12.65 billion by 2035, registering a CAGR of 9.95% during the forecast period from 2026 to 2035. The market growth is primarily driven by increasing investments by pharmaceutical companies in the development of novel therapeutics, along with the rising prevalence of genetic disorders across the globe.
Key Takeaways
- North America led the market with 44% share in 2025.
- Asia Pacific is expected to rise with the highest CAGR during the forecast period.
- By type of product synthesized, the finished dosage forms segment held the largest share of the market in 2025.
- By type of product synthesized, the active pharmaceutical ingredients segment is expected to expand at a significant CAGR during the forecast period.
- By therapeutic area, the rare diseases segment held the largest share of 44% in the market in 2025.
- By therapeutic area, the cardiovascular disorders segment is expected to grow at a considerable CAGR between 2026 and 2035.
- By company size, the large and very large segment held the largest share of 70% in the market in 2025.
- By company size, the mid-sized segment is expected to rise with a robust CAGR during the forecast period.
- By scale of operation, the commercial segment held the highest share of 78% in the market and is expected to grow significantly during the forecast period.
- By type of oligonucleotide synthesized, the antisense oligonucleotide segment dominated with 58% share in the market in 2025.
- By type of oligonucleotide synthesized, the siRNA segment is expected to grow at a notable CAGR during the forecast period.
- By scale of operation, the commercial segment dominated the market in 2025.
- By end-users, the pharmaceutical/biopharmaceutical companies segment held the largest share of the market in 2025.
Market Scope
| Report Coverage | Details |
| Market Size in 2025 | USD 4.90 Billion |
| Market Size in 2026 | USD 5.39 Billion |
| Market Size by 2035 | USD 12.65 Billion |
| Market Growth Rate from 2026 to 2035 | CAGR of 9.95% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | Type of Product Synthesized, Type of Product Synthesized, Company Size, Scale of Operation, Therapeutic Area, End-Users, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
What is the oligonucleotide synthesis market?
The oligonucleotide synthesis market represents a significant segment of the pharmaceutical and biotechnology industry, focusing on advanced technologies used for the synthesis of oligonucleotides. Oligonucleotide synthesis is a chemical process used to create customized DNA and RNA sequences, typically in the 3’-to-5’ direction, through the phosphoramidite method. The synthesis process involves a four-step cycle comprising detritylation, coupling, capping, and oxidation.
Growing investments in research and development activities aimed at advancing oligonucleotide-based therapies are playing a major role in driving market growth. Increasing efforts by pharmaceutical and biotechnology companies to improve treatment methodologies for genetic and chronic diseases are further supporting market expansion. Additionally, the rapid growth of the global biotechnology sector is expected to create substantial opportunities for the oligonucleotide synthesis market in the coming years.
AI in the Oligonucleotide Synthesis Market
Artificial intelligence (AI) is playing a transformative role in the oligonucleotide synthesis industry by improving accuracy, efficiency, and speed across the design and manufacturing processes. AI-powered technologies are helping accelerate drug discovery, optimize clinical trials, and enhance supply chain management capabilities within the pharmaceutical and biotechnology sectors.
In recent years, oligonucleotide synthesis companies have increasingly integrated AI into their manufacturing facilities to support custom sequence design, improve process optimization, and enable real-time production monitoring. The adoption of AI-driven systems also helps reduce operational costs, minimize human errors, and ensure the production of high-quality, customized oligonucleotides, thereby supporting the growing demand for advanced therapeutics and precision medicine solutions.
Major Market Trends
- Collaborations: Numerous biopharmaceutical brands are collaborating with genetic engineering companies to develop oligonucleotide therapeutics. For instance, in April 2025, Creyon Bio, Inc., collaborated with Eli Lilly and Company. This collaboration aims at accelerating the development of novel RNA-targeted oligonucleotide therapies for the treatment of rare and common diseases.
- Business Expansions: Various pharma companies are investing rapidly in opening new oligonucleotide manufacturing capacity in different parts of the world. For instance, in April 2024, ST Pharm invested around US$ 110 million. This investment is made to open an oligonucleotide manufacturing unit in Bandola, South Korea.
- Rising Prevalence of Cancers: The growing cases of cancers in different nations, such as the U.S., India, Germany, and the UAE, have increased the demand for oligonucleotide therapeutics. According to the American Cancer Society, around 324580 cases of new breast cancer are expected to be diagnosed in the U.S. during 2026.
Regional Insights
What is the North America Oligonucleotide Synthesis Market Size?
The North America oligonucleotide synthesis market was valued at approximately USD 2.16 billion in 2025 and is expected to reach nearly USD 5.63 billion by 2035, growing at a CAGR of 10.05% during the forecast period from 2026 to 2035.
Why Did North America Dominate the Oligonucleotide Synthesis Market?
North America dominated the oligonucleotide synthesis market by holding a major share in 2025. This is due to the increased prevalence of prostate cancer in numerous countries, such as Canada, the U.S., and Mexico. Also, numerous government initiatives aimed at strengthening the pharmaceutical sector, along with constant R&D activities related to oligonucleotide synthesis, are playing a vital role in shaping the industrial landscape. Moreover, investments and business expansions by several market players, such as Agilent Technologies, Thermo Fisher Scientific, and TriLink Biotechnologies, have driven the growth of the oligonucleotide synthesis market in this region.
What is the U.S. Oligonucleotide Synthesis Market Size?
The U.S. oligonucleotide synthesis market size is calculated at USD 1.62 billion in 2025 and is expected to reach nearly USD 4.25 billion in 2035, accelerating at a strong CAGR of 10.13% between 2026 and 2035.
U.S. Oligonucleotide Synthesis Industry Trends
The U.S. is a major contributor to the oligonucleotide synthesis market in North America. This is due to the surging focus of the pharmaceutical companies in developing advanced therapeutics for treating genetic disorders, as well as technological advancements in the biotech sector. Additionally, the growing demand for oligonucleotide therapeutics from public hospitals is contributing significantly to the industry.
Segment Insights
Company Size Insights
Why Did the Large and Very Large Segment Dominate the Oligonucleotide Synthesis Market?
The large and very large segment held the dominant share of the oligonucleotide synthesis market in 2025. The growth of this segment is primarily driven by increasing investments by major pharmaceutical companies in advanced technologies aimed at accelerating the drug discovery process.
Additionally, rising collaborations and partnerships between large biopharmaceutical companies and chemical manufacturers to develop innovative therapeutics for the treatment of rare diseases have further contributed to the expansion of this segment.
Oligonucleotide Synthesis Market Companies
- Integrated DNA Technologies provides custom oligonucleotide synthesis solutions, CRISPR technologies, and genomic products widely used in molecular biology and therapeutic research.
- Kaneka Eurogentec specializes in genomic and proteomic services, offering oligonucleotide synthesis and biopharmaceutical manufacturing solutions for research and clinical applications.
- LGC Biosearch Technologies delivers nucleic acid chemistry products, custom oligonucleotides, and genomic analysis solutions for diagnostics and pharmaceutical research.
- Merck offers advanced life science solutions, including oligonucleotide synthesis technologies and materials for pharmaceutical and biotechnology applications.
- STA Pharmaceutical/WuXi STA provides integrated CRDMO services, supporting oligonucleotide drug development and large-scale manufacturing for global pharmaceutical companies.
- Sumitomo Chemical develops advanced chemical and pharmaceutical products, including materials and intermediates used in oligonucleotide synthesis processes.
- Thermo Fisher Scientific supplies scientific instruments, reagents, and custom oligonucleotide synthesis services for research, diagnostics, and therapeutic development.
- TriLink BioTechnologies specializes in modified nucleic acids, mRNA technologies, and custom oligonucleotide manufacturing for vaccines and therapeutic applications.
- Microsynth provides DNA/RNA synthesis, sequencing, and molecular diagnostics solutions for academic, clinical, and industrial research sectors.
- Nitto Avecia offers contract development and manufacturing services for oligonucleotide therapeutics and complex pharmaceutical compounds.
- RiboBio RNA-based research products, oligonucleotide synthesis, and innovative nucleic acid therapeutics for biomedical applications.
Check this report to: Immunochemistry Instruments and Reagents Market
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview: https://www.precedenceresearch.com/sample/7843
You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344